AiCuris announced today that data on the positive outcome of Letermovir (AIC246) tested in a phase 2b trial in transplant patients will be disclosed at several international meetings on behalf of the AIC246 study team.
Initially, Dr. Holger Zimmermann will present phase 2b data on Letermovir (AIC246) for the prevention of HCMV infections in patients after human blood precursor cell transplantation at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which will be held in London from 31st March to 3rd April 2012. Data will be presented during the session on late breaking news on Monday, 2nd April 2012 from 12:30 – 13:30 hrs.
Prof. Gerhard Ehninger will present the respective data at the EBMT (European Group for Blood and Marrow Transplantation) meeting in Geneva, Switzerland during the Session of the Infectious Disease Working Party at 03 April 2012 starting at 4pm.
Later this month on 18th April 2012 Dr. Holger Zimmermann will present an overview on Letermovir (AIC246) including clinical phase 2b data within the clinical symposium at the International Conference on Antiviral Research (ICAR) meeting in Sapporo, Japan.
"The data presented show important results indicating that Letermovir (AIC246) apart from meeting both primary endpoints for efficacy showed also a very good safety profile an thus will allow for a paradigm shift in treating patients at risk for developing HCVM infection or diseases," said Helga Rübsamen-Schaeff, CEO of AiCuris.
Pilates lowers blood pressure in hypertensive patients, study finds